Pacific Edge Limited (PFGTF) has released an update.
Pacific Edge Limited, a New Zealand-based cancer diagnostics firm, is actively involved in the consultation process for a new microhematuria guideline by the AUA, which is crucial for medical reimbursement policies. The company also faces a delay in the resolution of Medicare’s draft Local Coverage Determination affecting their Cxbladder tests, with an extension for stakeholder comments review. These developments will not be settled before Pacific Edge’s Annual Shareholder Meeting on September 24, 2024, contrary to earlier projections.
For further insights into PFGTF stock, check out TipRanks’ Stock Analysis page.
